10

TOBI. Available for over a decade in treating Pseudomonas aeruginosa in cystic fibrosis.

 
Important Safety Information full Prescribing Information www.fda.gov/medwatch

References:

  • TOBI [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009.
  • Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 1999;340:23-30.
  • LiPuma JJ. Microbiological and immunologic considerations with aerosolized drug delivery. Chest. 2001;120(suppl 3):118S-123S.